202 related articles for article (PubMed ID: 17028986)
1. Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors.
Cauley JA; Song J; Dowsett SA; Mershon JL; Cummings SR
Breast Cancer Res Treat; 2007 Apr; 102(2):181-8. PubMed ID: 17028986
[TBL] [Abstract][Full Text] [Related]
2. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
3. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
4. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
6. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and risk of postmenopausal breast cancer.
Grenier D; Cooke AL; Lix L; Metge C; Lu H; Leslie WD
Breast Cancer Res Treat; 2011 Apr; 126(3):679-86. PubMed ID: 20838879
[TBL] [Abstract][Full Text] [Related]
9. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
12. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
13. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study.
Cummings SR; Lee JS; Lui LY; Stone K; Ljung BM; Cauleys JA
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1047-51. PubMed ID: 15894651
[TBL] [Abstract][Full Text] [Related]
14. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
Grady D; Vittinghoff E; Lin F; Hanes V; Ensrud K; Habel LA; Wallace R; Macer J; Cummings SR; Shepherd J
Menopause; 2007; 14(3 Pt 1):391-6. PubMed ID: 17224859
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and mortality among older breast cancer survivors in the Study of Osteoporotic Fractures.
Reeves KW; Faulkner K; Modugno F; Hillier TA; Bauer DC; Ensrud KE; Cauley JA;
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1468-73. PubMed ID: 17627012
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
[TBL] [Abstract][Full Text] [Related]
17. Measures of adiposity and risk of breast cancer in older postmenopausal women.
Krebs EE; Taylor BC; Cauley JA; Stone KL; Bowman PJ; Ensrud KE
J Am Geriatr Soc; 2006 Jan; 54(1):63-9. PubMed ID: 16420199
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer.
Chen Z; Maricic M; Pettinger M; Ritenbaugh C; Lopez AM; Barad DH; Gass M; Leboff MS; Bassford TL
Cancer; 2005 Oct; 104(7):1520-30. PubMed ID: 16110508
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort.
Nelson RL; Turyk M; Kim J; Persky V
BMC Cancer; 2002 Sep; 2(1):22. PubMed ID: 12377099
[TBL] [Abstract][Full Text] [Related]
20. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure.
Shapiro CL; Phillips G; Van Poznak CH; Jackson R; Leboff MS; Woodard S; Lemeshow S
Breast Cancer Res Treat; 2005 Mar; 90(1):41-6. PubMed ID: 15770525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
